Breaking Finance News

Needham issued a report on Genocea Biosciences Inc (NASDAQ:GNCA), boosting its stock price target to $15.00 today

Boasting a price of $5.42, Genocea Biosciences Inc (NASDAQ:GNCA) traded -3.50% lower on the day. With the last stock price close up 17.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Genocea Biosciences Inc has recorded a 50-day average of $5.36 and a two hundred day average of $4.72. Volume of trade was up over the average, with 3,859,570 shares of GNCA changing hands over the typical 284,664

Genocea Biosciences Inc (NASDAQ:GNCA) had its price target upped to $15.00 by Needham in an issued report announced Thursday September 29, 2016. The latest stock price target implies a potential upside of 1.77% from the company's last stock price close.

On 4/1/2016, Stifel Nicolaus released a statement for Genocea Biosciences Inc (NASDAQ:GNCA) bumped up the target price from $11.00 to $13.00 that suggested an upside of 0.68%.

Performance Chart

Genocea Biosciences Inc (NASDAQ:GNCA)

With a total market value of $0, Genocea Biosciences Inc has with a one year low of $2.56 and a one year high of $8.20 .

A total of 6 equity analysts have released a research note on GNCA. Two equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $18.17.

General Company Details For Genocea Biosciences Inc (NASDAQ:GNCA)

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company's pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.